Copyright
©The Author(s) 2020.
World J Clin Cases. Dec 26, 2020; 8(24): 6396-6407
Published online Dec 26, 2020. doi: 10.12998/wjcc.v8.i24.6396
Published online Dec 26, 2020. doi: 10.12998/wjcc.v8.i24.6396
Time | Preconception | GA 23+ wk | GA 24+ wk | GA 24+ to 28 wk | Postpartum, 7-34 d |
Related clinical manifestations and immune related indicators | 24-h urine protein fluctuates around 3 g | ALT: 197 U/L; AST: 185 U/L | Hb: 87 g/L | Cr: 176 μmol/L | Hb: 77 g/L |
ALT: 465 U/L; AST: 525 U/L | ALT: 15 U/L; AST: 23 U/L | ||||
Cr: 163 μmol/L | Cr: 79 μmol/L | ||||
24-h urine protein 19.43 g | 24-h urine protein 5.81 g | ||||
C3: 0.60 g/L; C4: 0.11 g/L | C3: 0.45 g/L; C4: 0.16 g/L | ||||
SLE activity index (score) | 4 (proteinuria) | 9 (proteinuria, hematuria, fever) | 15 (proteinuria, hematuria, cylindruria, fever) | 9 (proteinuria, cylindruria, fever) | |
Immunosuppressant | AZA (dose: 50 mg/d) | AZA (dose: 75 mg/d) | MP injection (dose: 500 mg/d × 3 d, 300 mg/Q12 h × 2 d) | MP injection (dose: 40 mg/d, 80 mg/d × 3 d) | Rituximab 100 mg × 1/2 wk |
MP (dose: 4 mg /d) | MP injection (dose: 500 mg/d × 3 d) | Plasma adsorption therapy | AZA (dose: 75 mg/d) | CYC 200 mg × 2 wk | |
IVIg (dose: 20 g /d × 5 d) | HCQ (dose: 200 mg/d) | MP injection (dose: 40 + 30 mg/d × 2 d, 40 + 20 mg/d × 8 d) | |||
TAC (0.5 mg × 1 d, 0.25 mg × 2 d) | |||||
Clinical response | Hb: 93 g/L | Hb: 81 g/L | Hb: 85 g/L | ||
ALT: 56 U/L; AST: 39 U/L | ALT: 282 U/L; AST: 130 U/L | ALT: 23 U/L; AST: 10 U/L | |||
Cr: 102 μmol/L | Cr: 136 μmol/L | Cr: 82 μmol/L | |||
24-h urine protein fluctuates around 19.68 g | 24-h urine protein 4.40 g | ||||
C3: 0.52 g/L; C4: 0.10 g/L | C3: 0.68 g/L; C4: 0.18 g/L |
Serial | No. | Diagnostic indexes | |
Clinical manifestation | 1 | Fever (37.6-40 °C) | |
2 | Acute cutaneous lupus erythematosus (“butterfly rash”, “discoid Rash”) | ||
3 | Serositis (lung CT images: Serous membrane fluid) | ||
4 | Synovitis (mild joint pain of wrist joint of both hands) | ||
5 | Blood system involvement (leukopenia 2.3 × 109/L, hemolytic anemia 95 g/L, thrombocytopenia 50 × 109/L; ESR 37 mmHg) | ||
6 | Renal system involvement (24-h urine protein 5422.00 mg; RBC under microscope: ++/HP, protein: +2, RBC morphological information: Heterogeneous cell type) | ||
7 | Aphthous ulcers | ||
Immunological indicators | 8 | ANA level above laboratory reference range (1:1000) | |
9 | Anti-dsDNA antibodies (+) | ||
10 | Anti-SSA (+) | ||
11 | Anti-Sm antibodies (+) | ||
12 | Antiphospholipid antibodies (IgA 4.21 mg/L, IgG 18.5 g/L) | ||
13 | Low complement (C3: 0.21 g/L, C4: 0.04 g/L) | ||
14 | CD3+CD4+CD28CD4 (37.0%) |
- Citation: Xiong ZH, Cao XS, Guan HL, Zheng HL. Immunotherapies application in active stage of systemic lupus erythematosus in pregnancy: A case report and review of literature. World J Clin Cases 2020; 8(24): 6396-6407
- URL: https://www.wjgnet.com/2307-8960/full/v8/i24/6396.htm
- DOI: https://dx.doi.org/10.12998/wjcc.v8.i24.6396